These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29476411)

  • 1. Evaluation of adequacy of levo-thyroxine dosage in patients with differentiated thyroid carcinoma: correlation between morning and afternoon TSH determination.
    Conte L; Monti E; Gay S; Marroni P; Adorno A; Mittica M; Mussap M; Giusti M
    J Endocrinol Invest; 2018 Oct; 41(10):1193-1197. PubMed ID: 29476411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients.
    Bolk N; Visser TJ; Kalsbeek A; van Domburg RT; Berghout A
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):43-8. PubMed ID: 17201800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH ultrasensitive assay, in patients receiving long term L-thyroxine suppression therapy and in patients with various thyroid disorders.
    Bartalena L; Martino E; Falcone M; Buratti L; Grasso L; Mammoli C; Pacchiarotti A; Aghini-Lombardi F; Balzano S; Pinchera A
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1265-71. PubMed ID: 3680483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of a Liquid Formulation of Levo-thyroxine in Differentiated Thyroid Cancer Patients.
    Giusti M; Mortara L; Machello N; Monti E; Pera G; Marenzana M
    Drug Res (Stuttg); 2015 Jun; 65(6):332-6. PubMed ID: 25020105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.
    Santoro AB; Vargens DD; Barros Filho Mde C; Bulzico DA; Kowalski LP; Meirelles RM; Paula DP; Neves RR; Pessoa CN; Struchine CJ; Suarez-Kurtz G
    Br J Clin Pharmacol; 2014 Nov; 78(5):1067-75. PubMed ID: 24910925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma.
    Giusti M; Cecoli F; Ghiara C; Rubinacci A; Villa I; Cavallero D; Mazzuoli L; Mussap M; Lanzi R; Minuto F
    Hormones (Athens); 2007; 6(4):304-13. PubMed ID: 18055421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
    Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
    Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing thyroid cancer without thyroxine withdrawal.
    Rosário PW; Vasconcelos FP; Cardoso LD; Lauria MW; Rezende LL; Padrão EL; Barroso AL; Guimarães VC; Purisch S
    Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):91-6. PubMed ID: 16628280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid liothyronine to obtain target TSH in differentiated thyroid cancer patients.
    Trimboli P; Centanni M; Virili C
    Endocr J; 2016 Jun; 63(6):563-7. PubMed ID: 27000530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individually-tailored thyroxine requirement in the same patients before and after thyroidectomy: a longitudinal study.
    Del Duca SC; Santaguida MG; Brusca N; Gatto I; Cellini M; Gargano L; Verga Falzacappa C; Frattaroli FM; Virili C; Centanni M
    Eur J Endocrinol; 2015 Sep; 173(3):351-7. PubMed ID: 26092761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.